SGLT2 inhibitors do not reduce 28-day mortality in hospitalized COVID-19 patients

Sodium glucose co-transporter-2 (SGLT2) inhibitors do not lead to lower 28-day all-cause mortality compared with usual care or placebo in patients hospitalized with COVID-19, according to late-breaking research presented in a Hot Line session today at ESC Congress 2023.

Rice360 celebrates expansion of newborn health program in Tanzania

Rice University President Reginald DesRoches joined Rice360 Institute for Global Health Technologies Co-Director Maria Oden and Rice360 supporters on a trip to Africa this summer

July 26, 2024

Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases – Biotech Investments

EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases 14.12.2023 / 07:30 CET/CEST The

December 15, 2023

Incyte’s checkpoint inhibitor staves off disease progression in anal cancer trial

BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients with a type of anal tumor, researchers reported Saturday, potentially

September 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.